对非酒精性脂肪性肝病的药理方法:当前和未来的治疗方法
1IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Diabetes spectrum : a publication of the American Diabetes Association
|February 22, 2024
概括
非酒精性脂肪肝病 (NAFLD) 和非酒精性脂肪肝炎 (NASH) 增加了严重疾病的风险. 对肥胖和2型糖尿病的早期药理治疗对于管理NASH和预防其进展至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 内分泌学 在内分泌学.
- 心血管医学 心血管医学
背景情况:
- 非酒精性脂肪性肝病 (NAFLD) 和其渐进的形式,非酒精性脂肪性肝炎 (NASH),与肝硬化,肝癌,心血管疾病和2型糖尿病有关.
- 2型糖尿病,特别是肥胖症,显著增加患NASH的风险.
研究的目的:
- 审查目前针对NAFLD和NASH的药理疗法.
- 讨论肥胖和2型糖尿病药物治疗在NASH管理中的作用.
- 提供对NASH新兴药物治疗方法的见解.
主要方法:
- 对当前临床指南的文献综述.
- 在NAFLD/NASH治疗中使用的药理学剂的分析.
- 关于新型NASH治疗方法的最新研究的综述.
主要成果:
- 生活方式的修改是基本的,但单独对NASH管理是不够的.
- 药理学药物如pioglitazone,GLP-1RA和SGLT2抑制剂在治疗NASH方面显示出有前途.
- 一些新的药物正在研究纳什治疗.
结论:
- 对肥胖和2型糖尿病的早期药理干预对于治疗NASH和预防疾病进展至关重要.
- 目前和新兴的药物疗法为管理NAFLD和NASH提供了潜在的策略.
- 结合生活方式和药物治疗的综合治疗方法对于最佳的患者结果至关重要.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
Chronic Pancreatitis II: Collaborative Care
90
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
90
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Ultrasound II: Endoscopic Ultrasound and FibroScan
106
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
106
Diabetes: Management and Pharmacotherapy
283
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
283
Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K


